Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Full article:

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.